Vaccines

15 Nov 2017 Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors
13 Nov 2017 80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up
13 Nov 2017 NousCom's Neoantigen-based Vaccine Synergizes With NKTR-214 to Cure Established Tumors in Preclinical Model
12 Nov 2017 Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting
12 Nov 2017 Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults
10 Nov 2017 Inovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference
09 Nov 2017 Bavarian Nordic Announces Initiation of Phase 2 Booster Study of its Universal RSV Vaccine
08 Nov 2017 Immunovaccine Announces Regulatory Clearance for Phase 2 Clinical Trial Evaluating DPX-Survivac in Combination with Merck’s Checkpoint Inhibitor Pembrolizumab in DLBCL
08 Nov 2017 Batu Biologics Receives FDA Clearance for First Multi-Pronged Immunotherapy Targeting the Blood Vessels that Feed Cancer
08 Nov 2017 Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer
08 Nov 2017 Genocea Presents New Data Demonstrating the Power and Versatility of its ATLAS™ Antigen Identification Platform at SITC 2017
07 Nov 2017 Takeda’s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue in Children and Adolescents; New 18-Month Interim Phase 2 Data Published in The Lancet Infectious Diseases
06 Nov 2017 BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax™
06 Nov 2017 SOTIO Completes Enrolment of Phase III VIABLE Study in Late Stage Prostate Cancer
02 Nov 2017 United Neuroscience Presents Data for Phase 2 Active Vaccine Program UB-311 at the Clinical Trials on Alzheimer's Disease 2017 Meeting
02 Nov 2017 Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor
30 Oct 2017 Vaxart Announces Positive Safety and Immunogenicity Results for Its Oral Norovirus Vaccine in a Phase 1b Clinical Study
30 Oct 2017 FDA Approves the Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax™ in Patients with Advanced Breast Cancer
27 Oct 2017 CureVac Initiates Phase I Clinical Trial of RNAdjuvant® Candidate as Intratumoral Therapy for Solid Tumors
26 Oct 2017 Vaxart Announces Positive Topline Results for its Oral Tablet Vaccine in Phase 2 Influenza Challenge Study
25 Oct 2017 Alopexx completes first-in-man trial of its novel, broad-spectrum anti-microbial vaccine
24 Oct 2017 Inovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study
23 Oct 2017 Shingrix approved in the US for prevention of shingles in adults aged 50 and over
21 Oct 2017 DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age
18 Oct 2017 Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top